Advanced search
1 file | 88.34 KB

Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6 polymorphisms

Author
Organization
Abstract
The cornerstone of pharmacotherapy for OCD is serotonin reuptake inhibition, either with clomipramine or with selective serotonin reuptake inhibitors (SSRIs). In spite of the success of serotonin reuptake inhibiting drugs, nearly half of OCD patients do not respond to treatment. Treatment response may be affected by genetic polymorphisms of the P450 metabolic system. The four most common enzyme-activity reducing polymorphisms of the P450 CYP2D6 enzyme were determined in 91 outpatients with primary OCD according to DSM-IV criteria, receiving dosages titrated upward to 300 mg/day of venlafaxine or 60 mg/day of paroxetine, using a fixed dosing schedule. Our results show that the investigated CYP2D6 polymorphisms are not a decisive factor in the response to paroxetine and venlafaxine treatment in OCD in spite of their highly significant effect on the blood levels of these medicines.
Keywords
plasma levels, OBSESSIVE-COMPULSIVE DISORDER, blood levels, response, polymorphisms, paroxetine, venlafaxine, CYP2D6, Obsessive-compulsive disorder, OCD, VENLAFAXINE, PAROXETINE, GENES, POPULATION

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 88.34 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Van Nieuwerburgh, Filip, Damiaan Denys, Herman Westenberg, and Dieter Deforce. 2009. “Response to Serotonin Reuptake Inhibitors in OCD Is Not Influenced by Common CYP2D6 Polymorphisms.” International Journal of Psychiatry in Clinical Practice 13 (4): 345–348.
APA
Van Nieuwerburgh, F., Denys, D., Westenberg, H., & Deforce, D. (2009). Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6 polymorphisms. INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 13(4), 345–348.
Vancouver
1.
Van Nieuwerburgh F, Denys D, Westenberg H, Deforce D. Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6 polymorphisms. INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE. 2009;13(4):345–8.
MLA
Van Nieuwerburgh, Filip et al. “Response to Serotonin Reuptake Inhibitors in OCD Is Not Influenced by Common CYP2D6 Polymorphisms.” INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE 13.4 (2009): 345–348. Print.
@article{803015,
  abstract     = {The cornerstone of pharmacotherapy for OCD is serotonin reuptake inhibition, either with clomipramine or with selective serotonin reuptake inhibitors (SSRIs). In spite of the success of serotonin reuptake inhibiting drugs, nearly half of OCD patients do not respond to treatment. Treatment response may be affected by genetic polymorphisms of the P450 metabolic system. The four most common enzyme-activity reducing polymorphisms of the P450 CYP2D6 enzyme were determined in 91 outpatients with primary OCD according to DSM-IV criteria, receiving dosages titrated upward to 300 mg/day of venlafaxine or 60 mg/day of paroxetine, using a fixed dosing schedule. Our results show that the investigated CYP2D6 polymorphisms are not a decisive factor in the response to paroxetine and venlafaxine treatment in OCD in spite of their highly significant effect on the blood levels of these medicines.},
  author       = {Van Nieuwerburgh, Filip and Denys, Damiaan and Westenberg, Herman and Deforce, Dieter},
  issn         = {1365-1501},
  journal      = {INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE},
  language     = {eng},
  number       = {4},
  pages        = {345--348},
  title        = {Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6 polymorphisms},
  url          = {http://dx.doi.org/10.1080/13651500902903016},
  volume       = {13},
  year         = {2009},
}

Altmetric
View in Altmetric
Web of Science
Times cited: